Background
The human SCN2A gene encodes the pore-forming subunit of Nav1.2, a voltage-gated sodium channel expressed in CNS neurons. SCN2A mutations are associated with benign familial neonatal-infantile seizures. Nav1.2 channels are therapeutic targets in seizure, stroke, and pain.
| General Info | |
| Synonyms | Brain type II |
|---|---|
| Product Description | Human Nav1.2 sodium ion channel-expressing, stable replicating cell line (CHO). |
| Target Type | Ion Channel |
| Product Type | Replicating Cell Line |
| Family | Sodium, Voltage-Gated |
| Sub-Type | Nav1.2 |
| Class | Voltage-gated sodium channel |
| Therapeutic Area | neurodegeneration & stroke, pain & inflammation, seizure-convulsion |
| Related Services | Large-scale Cryopreservation |
| Gene Name | SCN2A |
| Validated Assay/Platform | IonWorks Quattro™, QPatch HT |
| References | Catterall WA, et al. 2005. Pharmacol Rev 57:397-409. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels |
| Host cell | CHO |
| Mycoplasma Status | Negative (MycoAlert Kit) |
| Storage & Packaging | |
| Packaging | Cryopreserved cells, 1-2x106 cells |
| Storage Recommendation | liquid nitrogen |
| Quantity | 1-2 million cells |
| Product Documentation | |
| Specification Sheet | |



